Cargando…

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes

High-grade serous ovarian cancer (HGSOC) is one of the deadliest cancers that can occur in women. This study aimed to investigate the molecular characteristics of HGSOC through integrative analysis of multi-omics data. We used fresh-frozen, chemotherapy-naïve primary ovarian cancer tissues and match...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Min-Hwan, Kim, Se Ik, Shin, Jong-Yeon, Kim, Hee Seung, Chung, Hyun Hoon, Kim, Jae-Weon, Lee, Maria, Seo, Jeong-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303300/ https://www.ncbi.nlm.nih.gov/pubmed/34356119 http://dx.doi.org/10.3390/genes12071103

Ejemplares similares

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
por: Choi, Min Chul, et al.
Publicado: (2020)

Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2023)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer
por: Kim, Jisoo G., et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
por: Chien, Jeremy, et al.
Publicado: (2015)

Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients
por: Feng, Zheng, et al.
Publicado: (2021)

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
por: Su, Rongjia, et al.
Publicado: (2021)

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
por: Guarischi-Sousa, Rodrigo, et al.
Publicado: (2023)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins
por: Ye, Qingqing, et al.
Publicado: (2014)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
por: van Wagensveld, Lilian, et al.
Publicado: (2022)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
por: Lin, Sangdi, et al.
Publicado: (2018)

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
por: Roering, Pia, et al.
Publicado: (2022)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
por: Hillman, R Tyler, et al.
Publicado: (2017)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

Molecular classification and immunologic characteristics of immunoreactive high‐grade serous ovarian cancer
por: Liu, Zheran, et al.
Publicado: (2020)

Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
por: Kassuhn, Wanja, et al.
Publicado: (2021)

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
por: Handley, Katelyn F., et al.
Publicado: (2022)

Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer
por: Jönsson, Jenny-Maria, et al.
Publicado: (2021)

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
por: Kang, Hyo Jeong, et al.
Publicado: (2013)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_orqan14julgp78itjpukc90n9b